Embedded Files
Building a Multi-Modality Pipeline
Building a Multi-Modality Pipeline
BioAuraGen's licensed dual-targeting CAR-T programs form the foundation of a growing oncology pipeline focused on innovative therapies for hematologic malignancies and future multi-modality development.
Tier 1
Tier 1
PLATFORM CORE
Autologous CAR-T
Demonstrated end-to-end, same engine building BCMA×CD70 and CLL1×CD70 constructs.
Binder discovery, construct architecture, and screening cascade with no new capability required.
Tier 2
Tier 2
PLAUSIBLE EXTENSION
Allogeneic CAR-T · CAR-NK · Bispecific · ADC
Deploys the validated binder. Requires external manufacturing or protein-engineering capability to realize (gene editing, NK process, conjugation chemistry, recombinant production).
Field-wide precedent exists for each format on related targets.
Tier 3
Tier 3
SPECULATIVE / FURTHER REACH
Tri-specific · CAR-NKT · CAR-M
Greater engineering distance from platform's demonstrated core; thin or no field precedent for these specific target pairs.
IN DEVELOPMENT OR PLAUSIBLE
IN DEVELOPMENT OR PLAUSIBLE
Binder + CAR cassette
FUTURE-FORWORD
FUTURE-FORWORD
Different effector mechanisms with early field precedent
BINDER-PORTABLE
BINDER-PORTABLE
Reuses binder only with new protein engineering required
MULTI-ARM / COMPLEX
MULTI-ARM / COMPLEX
Greater engineering distance from platform core
Page updated
Report abuse